Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
PTC Therapeutics (PTCT)
NASDAQ:PTCT
Holding PTCT?
Track your performance easily
PTCT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$23.58 - $54.16
Previous CloseN/A
Volume146.45K
Average Volume (3M)716.91K
Market Cap
$3.39B
Enterprise Value$2.24B
Total Cash (Recent Filing)$231.67M
Total Debt (Recent Filing)$98.22M
Price to Earnings (P/E)―
Beta1.82
Next Earnings
Feb 25, 2025EPS Estimate
-0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.94
Shares Outstanding77,125,145
10 Day Avg. Volume509,940
30 Day Avg. Volume716,906
Standard Deviation0.13
R-Squared0.06
Alpha0.00141
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.76
Price to Cash Flow (P/CF)-11.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.66
Enterprise Value/Revenue2.49
Enterprise Value/Gross Profit2.57
Enterprise Value/Ebitda-12.62
Forecast
1Y Price Target
$53.82Price Target Upside22.18% Upside
Rating ConsensusHold
Number of Analyst Covering12
PTC Therapeutics News
PremiumCompany Announcements
PTC Therapeutics Surpasses Revenue Guidance for 2024
Bulls Say, Bears Say
Bulls Say
Financial PerformanceUnaudited full-year revenue for 2024 was $814 million, above consensus of $784 million.
Regulatory ProgressPTC continues to execute well, with Upstaza's PDUFA and sepiapterin's set for approval, and there is anticipation for both approvals.
Strategic PartnershipsPTC signed an exclusive global license agreement with NVS for PTC518 in Huntington's disease in exchange for $1B upfront, up to $1.9B in development, regulatory and sales milestones, a 40/60 profit share in the U.S., and double-digit tiered royalties ex-U.S.
Bears Say
Clinical Trial ResultsPTC Therapeutics reported that the phase 2 CardinALS study evaluating utreloxastat in amyotrophic lateral sclerosis (ALS) failed to meet primary and secondary efficacy endpoints.
Financial PerformancePTC announced a Q2 net loss of $99.2MM or $1.29/share vs. our estimated net loss of $86.5MM or $1.13/share and consensus of $1.12/share.
Regulatory ChallengesTranslarna's NDA was accepted for review, but the FDA has not provided review timelines and approval remains uncertain due to the regulatory history.
---
Ownership Overview
1.41% Insiders
27.01% Mutual Funds
0.09% Other Institutional Investors
54.26% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PTCT FAQ
What was PTC Therapeutics’s price range in the past 12 months?
PTC Therapeutics lowest stock price was $23.58 and its highest was $54.16 in the past 12 months.
What is PTC Therapeutics’s market cap?
PTC Therapeutics’s market cap is $3.39B.
When is PTC Therapeutics’s upcoming earnings report date?
PTC Therapeutics’s upcoming earnings report date is Feb 25, 2025 which is in 41 days.
How were PTC Therapeutics’s earnings last quarter?
PTC Therapeutics released its earnings results on Nov 07, 2024. The company reported -$1.39 earnings per share for the quarter, beating the consensus estimate of -$1.521 by $0.131.
Is PTC Therapeutics overvalued?
According to Wall Street analysts PTC Therapeutics’s price is currently Undervalued.
Does PTC Therapeutics pay dividends?
PTC Therapeutics does not currently pay dividends.
What is PTC Therapeutics’s EPS estimate?
PTC Therapeutics’s EPS estimate is -0.7.
How many shares outstanding does PTC Therapeutics have?
PTC Therapeutics has 77,125,145 shares outstanding.
What happened to PTC Therapeutics’s price movement after its last earnings report?
PTC Therapeutics reported an EPS of -$1.39 in its last earnings report, beating expectations of -$1.521. Following the earnings report the stock price went up 3.073%.
Which hedge fund is a major shareholder of PTC Therapeutics?
Among the largest hedge funds holding PTC Therapeutics’s share is Blackstone Inc.. It holds PTC Therapeutics’s shares valued at 41M.
---
PTC Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$53.82 (22.18% Upside)
$53.82 (22.18% Upside)
Blogger Sentiment
Bullish
PTCT Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 12.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 3.9%
Last 30 Days ▲ 3.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
61.17%
12-Months-Change
Fundamentals
Return on Equity
42.98%
Trailing 12-Months
Asset Growth
46.22%
Trailing 12-Months
Company Description
PTC Therapeutics
PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.
---
PTCT Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong financial performance, significant pipeline progress, and strategic NDA submissions and approvals. However, challenges remain in the European regulatory landscape and competitive pressures in the U.S. market.Read More>---
PTCT Stock 12 Month Forecast
Average Price Target
$53.82
▲(22.18% Upside)
Technical Analysis
Sarepta Therapeutics
―
Vertex Pharmaceuticals
―
BioMarin Pharmaceutical
―
Ionis Pharmaceuticals
―
Ultragenyx Pharmaceutical
―
Bluebird Bio
―
Best Analysts Covering PTCT
1 Year
1 Year Success Rate
14/17 ratings generated profit
1 Year Average Return
+31.45%
reiterated a buy rating last month
Copying Joel Beatty's trades and holding each position for 1 Year would result in 82.35% of your transactions generating a profit, with an average return of +31.45% per trade.
---